Anti -human immunodeficiency virus type 1 (HIV-1) activity was assessed in HIV-1 -infected homosexual and bisexual men receiving 18 -36 MIU/day of recombinant interferon (IFN)-a2a for Kaposi's sarcoma (KS). The median baseline HIV-1 RNA level was 4.99 log 10 copies/mL. Seventeen subjects (68%) showed an RNA decline §.5 log 10 /mL, with a maximum at week 4 (median decline Å 1.91, range Å 3.64 -1.15; P Å .0007), after which RNA levels stabilized. Eight subjects (32%) with lower median initial CD4 / T cell counts (60 vs. 350 1 10 6 /L; P Å .01) did not show RNA responses. Neither RNA nor KS responses were negatively affected by IFN-a2a dose modifications. Anti-HIV responses of KS responders (n Å 15) and nonresponders (n Å 10) did not differ. Highdose IFN-a can exert potent anti-HIV activity that is not associated with anti-KS activity. lesions). KS responses were defined according to guidelines de-Reprints or correspondence (current affiliation): Dr. P. H. J. Frissen, Departscribed in detail elsewhere [10]. Subjects could not have received ment of Internal Medicine and Gastroenterology, Onze Lieve Vrouwe Gasthuis, any previous treatment for HIV infection and were not allowed to
Interferon (IFN)-a is a cytokine that is mainly produced infected subjects [8] . These disappointing clinical results might be due to the use of low-dose IFN-a, because high-dose IFN-by peripheral blood mononuclear cells after stimulation with various viral and nonviral stimuli. It is involved in the regula-a monotherapy for the treatment of HIV-related Kaposi's sarcoma (KS) has been reported to suppress HIV-1 p24 antigen tion of many cellular functions, resulting in antiviral, antitumor, and immunomodulatory activities [1] . Soon after it was discov-and provide clinical benefit [10, 11] . Therefore, we conducted a study to explore the anti-HIV ered that human immunodeficiency virus (HIV) causes AIDS, the antiretroviral capacity of IFN-a was demonstrated in vitro activity of high-dose recombinant IFN-a2a, using serum HIV-1 RNA quantification as the most reliable and exact viral pa- [2, 3] . The mechanisms of action of IFN-a in HIV infection are not fully elucidated. An important inhibitory action of IFN-rameter. We used stored serum samples from subjects who had participated in a KS treatment study with high-dose recombi-a on HIV replication is interference with assembly and budding of new HIV virions [4] . nant IFN-a monotherapy (27 -36 MIU/day) in 1988; all had demonstrated clear antitumor activity and an anti-HIV response Clinical results with IFN-a for the treatment of HIV infection have been discouraging. After the demonstration in vitro of [10] . In addition, that study found evidence of an association between antitumor and anti-p24 responses, which was later synergistic anti-HIV activity with IFN-a plus zidovudine [5], combinations of low-dose INF-a and zidovudine have been confirmed by others [11] . used in different clinical settings with different primary end points and viral parameters [6 -9]. However, the largest of Materials and Methods these studies showed no evidence of superior clinical benefit from combination therapy: It compared, in a randomized and quantitation of HIV RNA: Patients received IFN-a2a daily during the first 8 weeks; during the subsequent 4 weeks, regimens were modified according to the KS response at week 8. An HIV RNA response was defined as a decrease from baseline of at least .5 log 10 copies/mL at two consecutive time points (or for at least 1 month).
Intervention. The IFN-a used in this study was recombinant human IFN-a2a (Roferon; Roche, Basel, Switzerland) and was self-administered by subcutaneous injection. For days 1-5, subjects received doses that increased daily by stepwise increments (i.e., 3, 9, 18, 27 , and 36 MIU, respectively). Thereafter, for the first 8 weeks, subjects received 36 MIU/day if their body weight was §60 kg and 27 MIU if it was õ60 kg. After 8 weeks, IFN-a2a was administered every other day to patients with a partial KS response or stable disease. For those with a complete KS Figure 1 . Serum levels of HIV RNA relative to baseline levels in response or progressive disease, treatment was discontinued.
patients whose RNA levels declined in response to treatment with HIV-1 RNA quantification. Serum was stored at 070ЊC. Serum IFN-a2a. HIV-1 RNA was quantitated in once-thawed serum, using nucleic acid-based sequence amplification (Organon Teknika, Boxtel, Netherlands) [12] . The variation of quantitative results is within HIV-1 RNA response. In all subjects, the maximum change .5 log 10 copies/mL. The lower limit at which RNA can be reliably in serum HIV-1 RNA concentrations during IFN-a2a treatment quantified is 1000 copies/mL (3 log 10 copies/mL).
was observed at week 4 (median Å 0.79 log 10 /mL, range Å T cell subpopulations and HIV-1 p24 antigen. Peripheral blood CD4 / and CD8 / T lymphocyte subpopulations were enumerated 03.64 to /2.62; P Å .001). However, this group contained using dual-color immunofluorescence and flow cytometry. Serum RNA responders (n Å 17; 68%) as well as nonresponders (n HIV-1 p24 antigen was measured by a sandwich-type ELISA (Ab-Å 8; 32%). Seventeen HIV RNA responders showed RNA bott Laboratories, Abbott Park, IL). declines of §1 log 10 copies/mL, whereas the 8 RNA nonre-Statistics. Laboratory values for CD4 / cells and RNA were sponders showed clear increases relative to baseline (median not normally distributed, partially due to censoring of the data RNA increase Å 1.3 and 1.5 log 10 /mL at weeks 4 and 8, respec-(RNA). HIV-1 RNA results were log-transformed, and values betively). The RNA responders showed a median RNA decrease low the lower quantification limit were considered to contain 3 from baseline of 1.91 log 10 /mL (P Å .0007) at week 4 and log 10 RNA copies/mL. Baseline laboratory values are the means 1.78 log 10 /mL (P Å .005) at week 8 (figure 1). For 5 subjects of two pretreatment values (one assessment within 4-8 weeks (20%) at week 4 and 4 subjects (21%) at week 8 after the start before entry and one at the start of treatment). Fifteen subjects of IFN-a2a therapy, serum HIV-1 RNA levels were below the (60%) had only one pretreatment RNA value available. Comparisons between groups were conducted at weeks 0, 4, and 8, using quantification limit of the assay (3 log 10 /mL).
the Mann-Whitney U test. The HIV RNA response over time in Comparison of the baseline characteristics of the HIV RNA the total study population was tested by the Wilcoxon signed rank responders and nonresponders revealed that RNA nonrespondtest for paired observations. Comparisons of the proportion of ers had significantly lower median CD4 / T cell numbers than either HIV-1 RNA or KS responders and nonresponders stratified did the responders (60 vs. 350 1 10 6 /L; P Å .01). Five of the by CD4 / cell counts below or above 200 1 10 6 /L were tested by RNA responders (29%) versus 6 of the RNA nonresponders the x 2 test. The correlation between serum HIV-1 RNA and p24 (75%) had baseline CD4 / cell counts of õ200 1 10 6 /L, antigen concentrations was tested by Spearman's rank correlation whereas 12 RNA responders (71%) versus 2 nonresponders coefficient. All tests were two-sided, and significance was set at (25%) had baseline CD4 / cell counts of §200 1 10 6 /L (P Å P õ .05.
.032). Other baseline variables, such as age, p24 antigenemia, KS response, and RNA concentrations did not show differences (data not shown). During IFN-a2a therapy, CD4 / cell re-Results sponses (percentages and numbers) relative to baseline responses did not show different patterns between patient re-Study population. At baseline, the median CD4 / cell count was 280 1 10 6 /L (range Å 10 -670 1 10 6 ), and the median sponse groups at any analyzed time point (data not shown). The RNA nonresponder group included 2 of 3 subjects with serum HIV-1 RNA concentration was 4.99 log 10 copies/mL. Three subjects with only one baseline serum sample available censored baseline RNA levels of 3 log 10 copies/mL whose RNA concentrations became detectable during therapy. had HIV-1 RNA concentrations below the lower quantification limit of the RNA assay. In the 14 subjects (56%) with p24 KS response. Fifteen subjects (60%) showed a KS response, whereas 10 subjects (40%) showed progressive KS antigenemia ( §30 pg/mL), no correlation between serum HIV-1 RNA and p24 antigen concentrations was found at baseline disease. At baseline, mean age (35.2 vs. 39.7 years) and median baseline CD4 / cell counts (230 vs. 350 1 10 6 /L) were lower or at any analyzed time point thereafter (data not shown).
/ 9d31$$se29
07-24-97 11:56:02 jinfa UC: J Infect by serum HIV-1 RNA concentrations [13] . However, direct comparison of the two studies is hampered by differences in study designs, IFN-a preparations (natural human IFN-a or in the group of KS nonresponders than in the responders, but the difference was not significant. All subjects with HIV-1 IFN-an3, consisting of a mixture of different IFN-a species), and clinical parameters of the study populations (disease stage, RNA concentrations below the assay quantification limit at any time point belonged to the group of KS responders. RNA CD4 / cell counts, and HIV-1 RNA levels). Despite the present results, it should be emphasized that IFN-a2a exhibited no concentrations did not show different patterns between KS responders and nonresponders during the first 8 weeks of daily anti-HIV response in 32% of our subjects. This group of nonresponders might be slightly greater, considering that no serum IFN-a2a administration: at week 4, the median RNA concentration relative to baseline was 01.91 log 10 /mL (03.64 to /2.62) samples were available at week 8 for 6 subjects. However, these subjects were considered to be RNA responders because versus 01.47 log 10 /mL (02.28 to /1.9); at week 8, the median RNA concentration relative to baseline was 01.41 log 10 /mL of unequivocal RNA declines at week 4. In addition, only 1 of 8 RNA nonresponders showed a biphasic RNA response. (03.64 to /2.33) versus 01.48 log 10 /mL (01.92 to /1.65), respectively.
Although the number of RNA nonresponders is small, the increase of HIV-1 RNA levels in some of these subjects could Within the group of KS responders, RNA responses of subjects with either complete (n Å 2) or partial response (n Å 8) not be explained by noncompliance or intercurrent infections. The only significant difference between the RNA responders or with stable disease (n Å 5) were indistinguishable by RNA response (data not shown). At weeks 4 and 8, median CD4 / and nonresponders was the lower initial CD4 / cell counts in the latter group. The KS nonreponders also had lower baseline T cell counts relative to baseline were higher in the KS responders than in the nonresponders, although these differences did CD4 / cell counts than KS nonresponders; however the difference was not significant, probably due to the small sample size. not reach significance (/10 vs. 040 1 10 6 /L; P Å .09 at week 4; 0 vs. 040 1 10 6 /L; P Å .14 at week 8). Concomitant KS In various studies, CD4 / cell counts ú200 1 10 6 /L have been associated with favorable KS responses to IFN-a [10, 11] or and RNA responses were found in 10 subjects (40%), whereas a combined KS and RNA nonresponse was observed in 3 suppression of serum HIV p24 antigen levels (or both) [11, 14] . Adequate anti-HIV and anti-KS activities of IFN-a appear (12%). All other subjects (n Å 12; 48%) had divergent KS and RNA responses (table 1) .
to require a certain minimum level of cellular immunity. To date, the minimal effective dose of IFN-a in HIV infec-Dose-response relation. HIV RNA and KS responses in relation to the dose of IFN-a2a are listed in table 1. Full-dose tion is still unclear. Within the dose range of the current study ( §18 MIU/day up to week 8) no dose-effect relationship could therapy was considered to be treatment with 36 MIU IFN-a2a daily, whereas all other dosages were considered to be a re-be demonstrated, possibly due to the small sample size. One study using a new natural IFN-a at different dose levels (1, 5, duced IFN-a2a dose. Five subjects (20%) had dose modifications before week 8. Of them, 4 had toxicity-related dose reduc-and 12.5 -20 MIU three times a week) showed a dose-dependent anti-HIV effect [13]: In the highest dose group, 3 of 5 tions to 18 MIU daily and 1 had a short-lasting treatment interruption. Table 1 shows that neither the HIV RNA response subjects had §2.41 log 10 /mL RNA decline, whereas the decline of serum RNA concentrations was õ1 log 10 /mL with the two nor the KS response seems to be affected by a reduced IFN-a2a dose.
lower dose levels. Another study, using HIV p24 antigen as the viral parameter, demonstrated a dose-dependent p24 antigen After the KS response evaluation at week 8, treatment was stopped for 12 subjects because of progressive KS (n Å 8) or suppression even with the use of low-dose IFN-a (2 -6 MIU/ day) [9] . personal request, mainly because of side effects (n Å 4). Thir-/ 9d31$$se29 07-24-97 11:56:02 jinfa UC: J Infect
